Achieve Life Sciences Inc
SP4P
Company Profile
Business description
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Contact
22722 29th Drive SE
Suite 1000
BothellWA98021
USAT: +1 604 210-2217
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.00 | 36.40 | -0.39% |
| CAC 40 | 7,703.90 | 58.70 | -0.76% |
| DAX 40 | 23,902.21 | 137.71 | -0.57% |
| Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
| FTSE 100 | 9,187.34 | 29.48 | -0.32% |
| HKSE | 25,528.84 | 451.22 | 1.80% |
| NASDAQ | 21,455.55 | 249.61 | -1.15% |
| Nikkei 225 | 41,906.41 | 812.06 | -1.90% |
| NZX 50 Index | 13,000.64 | 69.91 | 0.54% |
| S&P 500 | 6,460.26 | 41.60 | -0.64% |
| S&P/ASX 200 | 8,911.20 | 37.60 | -0.42% |
| SSE Composite Index | 3,862.65 | 4.72 | 0.12% |